As organizations in the life sciences industry look to opportunities to generate greater returns and increase efficiencies, there’s a growing interest in AI-driven R&D processes among other aspects of the value chain. Netscribes ...

The COVID-19 pandemic has accelerated the demand for digital health services. With the healthcare sector at the forefront of this crisis, digital health presented itself as a perfect solution to transform healthcare into a more accessible, da...

Life sciences industry’s response to COVID-19 disruptions has evolved over the course of the year. The SARS-CoV-2 virus, first emerged as an unknown pneumonia-like disease in December 2019, and ultimately gained the status of a global h...

Formulating an ethical and potent vaccine against novel pathogens typically takes years. Globally, scientists, pharmaceutical firms, and regulators are arduously working to answer the most palpable question – a COVID-19 vaccine. While clini...

Ensuring environmental, health and safety (EHS) compliance in your supply chain is vital for mitigating third-party risk. Non-compliance can result in hefty fines and spell disaster for your company’s reputation. Procurement and compliance ...

Artificial Intelligence (AI) is bringing about a paradigm shift in healthcare, powered by the increasing availability of medical data and the rapid progress of analytical techniques. From catalyzing drug discovery to using data-driven diagnos...

Get a closer look at the technologies that are poised to bring major disruption across enterprises in 2018 and beyond. Towards the end of 2017, we saw some ground-breaking technologies come into the limelight. In 2018, we expect to see these ...

The rise of Internet of Things (IoT) is ushering us into the era of smart factories or Industrial 4.0. The global smart factory market, in terms of value, is expected to grow at a CAGR of 10.4% and reach USD 74.80 billion by 2020. The next ge...

The global biosimilar market is expected to reach USD 36 billion by 2022. However, only some countries are favorable for biosimilars due to reasons ranging from poor accessibility to unconducive regulatory environments. This infographic takes...

Contact Us
X
  • I agree to receive updates on the latest industry trends, products and services from Netscribes.
  • We respect your right to data privacy and security. You may unsubscribe from our communications at any time. For more information, check out our Privacy Policy.